New Index Rates Drug Companies in Fight Against ‘Superbugs’
New Index Rates Drug Companies in Fight Against ‘Superbugs’
Global Health By
DONALD G. McNEIL Jr.
JAN. 23, 2018
GlaxoSmithKline and Johnson & Johnson are the best of the big pharmaceutical companies at tackling the growing
"superbug" threat, according to an index released Tuesday at the World Economic Forum in Davos, Switzerland.
Companies were judged by several criteria, said Jayasree K. Iyer, executive director of the Access to
Medicines Foundation, which published the new index, called the Antimicrobial Resistance Benchmark.
The index, which rates companies on their contributions to preventing the spread of bacteria
that are resistant to antibiotics, found Mylan to be the best of the generic drug makers and rated a little-known company, Entasis, as top among biotechnology companies.
Tedros Adhanom Ghebreyesus said that a global health emergen
Drug companies have 28 new antibiotics in late stages of development, but only nine are markedly different from existing ones, Dr. Iyer said.
For example, Dr. Iyer said, Glaxo stopped tying sales agents’ bonuses to the volumes they sold
and rewarded them for customer service, technical knowledge and how well they help doctors prescribe judiciously.
Global Health By
DONALD G. McNEIL Jr.
JAN. 23, 2018
GlaxoSmithKline and Johnson & Johnson are the best of the big pharmaceutical companies at tackling the growing
"superbug" threat, according to an index released Tuesday at the World Economic Forum in Davos, Switzerland.
Companies were judged by several criteria, said Jayasree K. Iyer, executive director of the Access to
Medicines Foundation, which published the new index, called the Antimicrobial Resistance Benchmark.
The index, which rates companies on their contributions to preventing the spread of bacteria
that are resistant to antibiotics, found Mylan to be the best of the generic drug makers and rated a little-known company, Entasis, as top among biotechnology companies.
Tedros Adhanom Ghebreyesus said that a global health emergen
Drug companies have 28 new antibiotics in late stages of development, but only nine are markedly different from existing ones, Dr. Iyer said.
For example, Dr. Iyer said, Glaxo stopped tying sales agents’ bonuses to the volumes they sold
and rewarded them for customer service, technical knowledge and how well they help doctors prescribe judiciously.
Category
🗞
News